Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $26.0300 (-3.38%) ($25.3100 - $27.2000) on Fri. Jun. 26, 2015. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.24% (three month average) | | RSI | 80 | | Latest Price | $26.0300(-3.38%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | ADMS declines -0.5% a day on average for past five trading days. | | Weekly Trend | ADMS advances 14.9% a week on average for past two weeks. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability)
XBI(34%) IBB(32%) IWM(22%) XLV(21%) XOP(21%) | | Factors Impacting ADMS price | ADMS will decline at least -1.62% in a week (0% probabilities).
VIXM(-15%) BNDX(-10%) TLT(-7%) SHY(-7%) UUP(-5%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.62% (StdDev 3.24%) | | Hourly BBV | 0 () | | Intraday Trend | -3.7% | | | | | |
|
| 5 Day Moving Average | $26.4(-1.4%) | | 10 Day Moving Average | $25.73(1.17%) | | 20 Day Moving Average | $22.68(14.77%) | | To recent high | -3.8% | | To recent low | 55.7% | | Market Cap | $736m | | | | | | |
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |